HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Scigliano, G. Articles by Schechter, P. J. Search for Related Content PubMed PubMed Citation Articles by Scigliano, G. Articles by Schechter, P. J.

Gamma-vinyl GABA treatment of Huntington's disease

From the Istituto Neurologico "C. Besta" (Drs. Scigliano, Giovannini, Girotti, Grassi, and Caraceni), Milano, Italy, and Centre de Recherche Merrell International (Dr. Schechter), Strasbourg, France.

In a double-blind, crossover study -vinyl GABA, 2 g/day, and placebo were administered orally for 2 weeks each to six patients with Huntington's disease. Five patients were treated concomitantly with a neuroleptic maintained at constant dose. No consistent beneficial effects on the hyperkinetic movements, abnormal motor function, or ability to carryout normal activities were evident with -vinyl GABA treatment. Treatment was tolerated without clinically significant alterations in the physiologic or biochemical tests used for monitoring. These results suggest that increasing CNS GABAergic function is unlikely to ameliorate Huntington's disease.

Address correspondence and reprint requests to Dr. Caraceni, Istituto Neurologico "C. Besta," Via Celoria, 11, 20133 Milano, Italy.

Accepted for publication April 13, 1983.